Shandong Wohua Pharmaceutical 沃华医药
3 significant filings since 30 May 2026: 1 on dividend, 1 on earnings pre-announcement and 1 on major holder selling. The latest, on 12 Aug 2026: 2026年中期权益分派实施公告. On 7 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 45.49% to 79.07% from the same period a year earlier.
自 30 May 2026 起有 3 份重大公告：dividend 1 份、earnings pre-announcement 1 份、major holder selling 1 份。最新一份（12 Aug 2026）：2026年中期权益分派实施公告。7 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 45.49% 至 79.07%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥41亿 | ¥61亿 | 20th lowest of 66 · 66 家中第 20 低 | |
| Trailing P/E 市盈率 | 34.9x | 31.3x | 22nd highest of 49 · 49 家中第 22 高 | |
| P/B 市净率 | 5.9x | 2.2x | 5th highest of 65 · 65 家中第 5 高 | |
| Revenue Growth 营收增速 | -7.5% | -7.4% | 32nd lowest of 66 · 66 家中第 32 低 | |
| Profit Growth 净利增速 | 51.2% | -0.2% | 11th highest of 66 · 66 家中第 11 高 | |
| Gross Margin 毛利率 | 77.8% | 56.9% | 6th highest of 66 · 66 家中第 6 高 | |
| Net Margin 净利率 | 18.1% | 9.6% | 20th highest of 66 · 66 家中第 20 高 | |
| Return on Equity 净资产收益率 | 9.4% | 3.0% | 5th highest of 65 · 65 家中第 5 高 | |
| Debt to Assets 资产负债率 | 26.3% | 28.4% | 30th lowest of 66 · 66 家中第 30 低 | |
| Grade Score 评级得分 | 70 | 52 | 7th highest of 66 · 66 家中第 7 高 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥890亿 | 17.0x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥708亿 | 39.1x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥389亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥315亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥289亿 | 16.2x | 2.8x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥271亿 | 31.9x | 4.6x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥225亿 | 12.2x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥209亿 | 6.6x | 0.7x | -8.5% | 198.7% | 6.5% | C |
| Tasly 天士力 | ¥204亿 | 16.7x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥198亿 | 99.6x | 5.0x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥184亿 | 624.3x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥153亿 | 65.0x | 1.5x | -11.7% | 9.2% | 4.9% | D |
| Shandong Wohua Pharmaceutical 沃华医药 | ¥41亿 | 34.9x | 5.9x | -7.5% | 18.1% | 9.4% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。